Preview Newsletter
XARELTO Media Monitoring – Week of 02-12-16
-
Xarelto Lawsuit From Ohio Woman Alleges Drug Caused Her Severe Gastrointestinal Bleed
Feb 5, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of corporate giant Johnson & Johnson), the manufacturers of blood-thinning drug Xarelto. The plaintiff, in this case, is an Ohio woman who alleges that the anticoagulant caused her to suffer a dangerous gastrointestinal bleed, leaving her with a need for longer-term medical care due to the damaging side effects she has sustained. -
Xarelto Lawsuit Plaintiffs Encouraged By Similarities To Settled Pradaxa Lawsuits
Feb 5, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on some of the similarities between Xarelto lawsuits and previously settled Pradaxa lawsuits, which provide comfort and hope to plaintiffs looking to pursue justice. Xarelto lawsuits now number over 3,000. There are more than 2,800 cases filed in federal courts and consolidated to form MDL no. 2592, and, additionally, there are over 550 cases which have been consolidated to form a mass tort group in Philadelphia, Pennsylvania. Lawsuits which make up multidistrict litigation number 2592 were consolidated by the U.S. Judicial Panel on Multidistrict Litigation and are currently being overseen by the Honorable Judge Eldon Fallon in New Orleans. -
Plaintiff Files Xarelto Lawsuit Claiming Anticoagulant Caused Mans Uncontrollable Internal Bleeding Death
Feb 5, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which now joins with over 2,800 similar cases federally- filed which were consolidated by the JPML to form Xarelto multidistrict litigation No.2592. This case was filed in the Eastern District of Louisiana, where the MDL is located, under number 2:15-cv-00885. It was filed by a son, on behalf of his father who had suddenly and unexpectedly passed away after an emergency internal bleeding event. According to the son’s allegations, the man’s uncontrollable internal bleeding episode had been caused by blood-thinning drug Xarelto. Because of this, he has now filed a lawsuit against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). -
Xarelto Lawsuit News: Federal Multidistrict Litigation Convenes January Status Conference, Bernstein Liebhard LLP Reports
Feb 8, 2016 | Berstein Liebhard LLP
Thousands of Xarelto lawsuits (www.rxinjuryhelp.com/xarelto/lawsuit) continue to move forward in the federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, where the most recent monthly Status Conference was convened on January 22, 2016. A Minute Entry notes that, among other things, the parties exchanged bellwether trial selections on January 11th, while random selections were made on January 15th. The Entry also indicates that the Court will hear oral arguments on a proposed order governing the parties’ interactions with plaintiffs’ prescribing and treating physicians on February 23rd, immediately following the Status Conference scheduled for that date. (In Re: Xarelto Products Liability Litigation, No. 2592) -
Xarelto Lawsuit Alleges Manufacturers Fraudulently Marketed Blood Thinning Drug
Feb 8, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against the manufacturers of anticoagulant Xarelto: Janssen Pharmaceuticals (part of the Johnson & Johnson corporation) and Bayer AG. This complaint alleges that each of these companies has fraudulently misrepresented the risks and benefits of the blood thinner through misleading marketing tactics. The complaint encompasses a total of 32 counts and was filed in the St. Clair County Circuit Court on October 13, 2015, under case number 15-L-581. -
Plaintiffs Filing Xarelto Lawsuits Find Support From Studies Linking Drug Use To Sudden Bleeding Episodes
Feb 8, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the results of several studies which have stirred up new concerns over the use of blood thinner Xarelto by linking it to dangerous, sudden bleeding episodes in patients. This supports the arguments of the many plaintiffs who have recently filed lawsuits against Xarelto, who all commonly allege that the anticoagulant can cause serious and even fatal uncontrollable bleeding side effects for those using it. -
Xarelto Lawsuit Plaintiff Claims Manufacturers Use Misleading Advertisements for Anticoagulant
Feb 9, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against the makers of blood-thinning drug Xarelto, Bayer AG and Janssen Pharmaceuticals. The complaint discusses recent marketing advertisements which the plaintiff indicates are intentionally misleading. The drug, which is currently the subject of over 2,800 federal court lawsuits and over 550 lawsuits in a Philadelphia, Pennsylvania mass tort group, still uses the endorsements of famous celebrities in its ads, which focus heavily on the good and, according to the plaintiff, do not adequately discuss Xarelto’s potentially dangerous side effects. -
Vermont Plaintiff Files Xarelto Lawsuit Alleging Drug Caused Father's Fatal Uncontrollable Bleed
Feb 9, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit filed against the manufacturers of anticoagulant Xarelto: Bayer AG and Janssen Pharmaceuticals, (a division of the Johnson & Johnson corporation). The lawsuit was filed under case number 2:14-cv-00159-CR by a daughter on behalf of her deceased father in a Vermont federal courtroom. The complaint alleges that the plaintiff’s father’s uncontrollable bleeding episode and subsequent death was caused by Xarelto. -
Xarelto Lawsuit Study Published by BMJ Notes Possible Twofold Increase in GI Bleed Risk
Feb 9, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the concerning results of several studies that appear to connect the use of anticoagulant Xarelto to increased risk of dangerous bleeding episodes, such as spontaneous vitreous hemorrhages, (also known as eye bleeds), and internal gastrointestinal bleeds. -
Xarelto Lawsuit Plaintiff Draws Questions Surrounding Drug’s 24 Hour, One-Pill Dosage
Feb 10, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an especially remarkable Xarelto lawsuit which was filed in a State Court in Pennsylvania. The suit names Xarelto manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson) as the defendant, and is especially notable as it poses a different claim than many of the others. -
Xarelto Lawsuits Continue Their Steady Progression As Plaintiffs Look To February Status Conference
Feb 10, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto lawsuits consolidated in MDL No. 2592, which continue to progress in the U.S. District Court for the Eastern District of Louisiana. The latest monthly status conference for these lawsuits was held on January 22nd of 2015, where those involved shared bellwether trial selections. -
Xarelto Lawsuit Plaintiff Draws Questions Surrounding Drugs 24 Hour, One-Pill Dosage
Feb 10, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an especially remarkable Xarelto lawsuit which was filed in a State Court in Pennsylvania. The suit names Xarelto manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson) as the defendant, and is especially notable as it poses a different claim than many of the others. -
Xarelto Lawsuit Plaintiffs Involved In MDL No. 2592 Look Ahead To Bellwether Trial Dates For Early 2017
Feb 11, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on bellwether trial dates which have been set for Xarelto-related lawsuits consolidated in multidistrict litigation no. 2592. The MDL cases are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana and underwent bellwether trial preparations in early January of 2016. -
Xarelto Lawsuits In Philadelphia Mass Tort Group Allege Blood Thinner Causes Uncontrollable Bleeding Risks
Feb 11, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the steady increase of Xarelto lawsuit numbers being consolidated to form a mass tort group in Philadelphia, Pennyslvania by the Court of Common Pleas. These lawsuits were commonly filed against defendants Bayer AG and Janssen Pharmaceuticals, (whose parent company is corporate giant Johnson & Johnson). -
Xarelto Lawsuits Now Exceed 3,000 in Number
Feb 11, 2016 | Legal-Bay
By Patty Kirby
Legal-Bay LLC, The Lawsuit Settlement Funding Company, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division are now more than 3,000 in number. Just last month, the number of cases were at approximately 2,400. Now, according to the Blood Thinner Help website, 2,800 cases have been consolidated in the Eastern District of Louisiana, with an additional 550 lawsuits consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania (MDL 2592). -
New Jersey Woman Blames Xarelto for Life-Threatening Bleeding
Feb 9, 2016 | Legal Examiner
By Kendra Goldhirsch
On December 28, 2015, another Xarelto lawsuit joined the centralized litigation in the Eastern District of Louisiana. The plaintiff, a resident of New Jersey, brought claims against manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson, and Bayer Pharma AG. There are currently over 2,400 Xarelto lawsuits pending in Louisiana, in which plaintiffs claiming that the manufacturers failed to warn about serious risks associated with the blood-thinning drug, including serious gastrointestinal bleeding that can lead to death. -
Xarelto Uncontrollable Brain Bleed Lawsuits Increasing
Feb 9, 2016 | Dallas Fort Worth Injury Lawyer Blog
By Dr. Shezad Malik
Oren Fells from Georgia recently filed a Xarelto uncontrollable intracranial or brain bleeding lawsuit in the U.S. District Court for the Eastern District of Louisiana. The lawsuit was filed against Bayer Healthcare, Johnson & Johnson, and its Janssen subsidiary, the manufacturers of Xarelto. -
Xarelto Lawsuit Says Blood Thinner Caused Intracranial Bleed
Feb 9, 2016 | Top Class Actions
By Joanna Szabo
A Georgia resident recently filed a lawsuit against Janssen, a subsidiary of Johnson & Johnson, over Xarelto problems including internal bleeding in the brain. -
Can Xarelto Trial Data Be Trusted? It Depends Who You Ask
Feb 10, 2016 | LawyersAndSettlements.com
By Heidi Turner
As more Xarelto lawsuits are added to the multidistrict litigation, concerns have been raised that a medical device used in Xarelto’s clinical trial was faulty, which may have affected test results. Now critics are asking for an investigation, while Janssen Pharmaceuticals and the study’s authors maintain the study’s conclusions are accurate. -
Georgia Man Suffers Brain Hemorrhage After Taking Xarelto
Feb 11, 2016 | Legal Examiner
By Roopal Luhana
On January 9, 2016, another Xarelto lawsuit joined the consolidated litigation in the Eastern District of Louisiana. The MDL was sent there in December 2014. -
Blood Thinner Lawsuit: Xarelto Causes Serious Gastrointestinal Bleeding
Feb 12, 2016 | Top Class Actions
By Ashley Vanover
Although Xarelto was approved for use in 2011 and is one of the newest blood thinners on the market, it is also the subject of lawsuits alleging that the blood thinner puts patients at risk for dangerous side effects, including life-threatening internal bleeding. -
Dallas Xarelto Lawyer
Feb 12, 2016 | Rasanky Law Firm
Individuals who are at an increased risk of blood clot formation are advised to take blood thinners by their doctors. Xarelto®, the number one blood thinner in the U.S. as of 2014, is used widely to help dissolve blood clots which could turn fatal if they traveled from their point of formation (usually deep within a vein located in the person’s leg) to the lungs or the brain.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Xarelto Lawsuit From Ohio Woman Alleges Drug Caused Her Severe Gastrointestinal Bleed
Feb 5, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of corporate giant Johnson & Johnson), the manufacturers of blood-thinning drug Xarelto. The plaintiff, in this case, is an Ohio woman who alleges that the anticoagulant caused her to suffer a dangerous gastrointestinal bleed, leaving her with a need for longer-term medical care due to the damaging side effects she has sustained.
The plaintiff noted in lawsuit details that she was prescribed Xarelto by her physician in order to treat her atrial fibrillation condition. Atrial fibrillation is a heart condition which is common but can put people suffering from it at an increased risk of stroke. Blood thinners are often prescribed in these cases as a preventative measure to help discourage the occurrence of a stroke. Although the woman did not have a stroke while on Xarelto, she alleges that she suffered an event equally as serious.
The plaintiff claims that she had been using the drug under one year’s time when she suffered from a spontaneous and severe gastrointestinal bleeding episode. Xarelto has been repeatedly linked to these types of dangerous uncontrollable bleeding episodes, both external and internal, by plaintiffs from across the nation, and in multiple studies as well. In some cases, the bleeds become fatal and caused the death of the patients involved. In this case, the plaintiff survived but now alleges that the occurrence has left her with medical needs that will be long term.
The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011. The FDA approved the anticoagulant to treat patients who had undergone hip and knee replacement surgeries, or who are at risk of developing deep vein thrombosis (DVT), and to prevent blood clots and strokes. A bit later, the FDA also expanded the drug’s approved uses to include treatment for atrial fibrillation patients.
When Xarelto first came onto the market as a new-generation blood thinner, it was commonly thought of as revolutionary. Suddenly a blood thinner was available which required no regular monitoring or dosage adjustments by physicians. It also offered a convenient one pill per day dosage. Today, plaintiffs question all of these things. Some allege that one pill does not adequately protect someone taking it for a full 24-hour period; others say that the drug should require monitoring and that the lack of monitoring was part of the problem. All plaintiffs commonly agree that the defendants used misleading marketing tactics which focused on the benefits of the drug and neglected to properly communicate the many dangers associated with it.
At this time, Attorney Joseph Osborne is working to ensure that anyone who has suffered from an adverse health event after using Xarelto will have the opportunity to fully explore their legal options. Affected parties may be entitled to legal action and substantial compensation. Attorney Osborne also currently offers free legal consultations for those who qualify, to help them in their pursuit of justice.
To obtain additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wrcbtv.com/story/31154712/xarelto-lawsuit-from-ohio-woman-alleges-drug-caused-her-severe-gastrointestinal-bleed
-
Xarelto Lawsuit Plaintiffs Encouraged By Similarities To Settled Pradaxa Lawsuits
Feb 5, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on some of the similarities between Xarelto lawsuits and previously settled Pradaxa lawsuits, which provide comfort and hope to plaintiffs looking to pursue justice. Xarelto lawsuits now number over 3,000. There are more than 2,800 cases filed in federal courts and consolidated to form MDL no. 2592, and, additionally, there are over 550 cases which have been consolidated to form a mass tort group in Philadelphia, Pennsylvania. Lawsuits which make up multidistrict litigation number 2592 were consolidated by the U.S. Judicial Panel on Multidistrict Litigation and are currently being overseen by the Honorable Judge Eldon Fallon in New Orleans.
Consolidated cases all contain similar allegations and have been filed against defendants Bayer Healthcare and Janssen Pharmaceuticals, (a subdivision of Johnson & Johnson corporation). Plaintiffs involved all commonly claim that blood-thinning drug Xarelto can put users at increased risk for sudden and dangerous bleeding episodes, both internal and external, some of which can lead to death.
At the beginning of 2016, Judge Fallon required that plaintiffs and defendants involved each choose 10 cases to form a bellwether pool of 40 cases. From this pool, he noted that 4 cases would be chosen to be heard as bellwether trials in 2017. It is expected by many that as these cases await trial, others will join the MDL and mass tort group and lawsuits filed concerning the dangers of Xarelto will continue to increase in number.
Pradaxa is similar to Xarelto in that it is also considered a new-generation blood thinner. It was marketed by Boehringer Ingelheim in October, 2010. As plaintiffs are now seeing with the Xarelto cases, shortly after Pradaxa was released to market, it was surrounded by more than 3,500 reports of adverse health events. Over 750 of these cases reported the death of a patient who was using Pradaxa. The blood thinner quickly became the topic of more than 4,000 lawsuits from across the nation. The night before Pradaxa trials were set to begin, Boehringer Ingelheim chose to settle the cases by paying $650 million to plaintiffs.
Xarelto plaintiffs find hope in the result of these lawsuits as they prepare to face their own trials. At this time, there have not yet been talks of settlement from Bayer or Janssen. While trial preparations continue to take place, Attorney Joseph Osborne has been working to help ensure that everyone negatively affected by Xarelto will have the opportunity to fully investigate their legal rights. He is now offering free legal consultations for involved parties, to help encourage others to join in the fight for justice. It is believed that those who were negatively affected by the drug may be entitled to legal action and substantial compensation.
To ask questions, or to request additional information, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.kcentv.com/story/31154880/xarelto-lawsuit-plaintiffs-encouraged-by-similarities-to-settled-pradaxa-lawsuits
-
Feb 5, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which now joins with over 2,800 similar cases federally- filed which were consolidated by the JPML to form Xarelto multidistrict litigation No.2592. This case was filed in the Eastern District of Louisiana, where the MDL is located, under number 2:15-cv-00885. It was filed by a son, on behalf of his father who had suddenly and unexpectedly passed away after an emergency internal bleeding event. According to the son’s allegations, the man’s uncontrollable internal bleeding episode had been caused by blood-thinning drug Xarelto. Because of this, he has now filed a lawsuit against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation).
Accompanying the almost 3,000 federal court lawsuits in MDL 2592, the Court of Common Pleas in Philadelphia has formed a mass tort group of over 550 cases containing similar allegations against the same defendants. When cases contain very similar allegations, they can be consolidated to form larger groups to help expedite the litigation process. Consolidation helps legal proceedings to run more smoothly and efficiently and also helps to avoid duplicate discovery and different rulings from multiple judges. For involved parties, consolidation saves resources like time and finances.
This particular complaint was filed on March 20, 2015, and details within court documents indicate that the father was prescribed Xarelto as a treatment for his atrial fibrillation condition. This is a fairly common heart condition which can put patients at increased risk for strokes, so many people with this condition are preventatively prescribed blood thinners. Xarelto was approved by the FDA to treat individuals with this condition, as well as to treat those recovering from knee and hip replacements, or those who have developed deep vein thrombosis.
The son notes that he and his father were never made aware of the serious dangers associated with Xarelto, specifically the fact that, at the time, the drug offered no corresponding antidote to clot the blood during bleeding emergencies. Had they been made aware of this, according to the son, they would have used an alternative blood thinner, such as warfarin, which offers an antidote through vitamin K.
At this time, Attorney Joseph Osborne is working to ensure that everyone who has taken Xarelto and who later suffered from adverse health effects will be given the opportunity to fully evaluate their legal rights. These individuals may be entitled to substantial compensation. Attorney Osborne is currently offering free consultations to affected individuals as they look to pursue justice.
To request additional information or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.kcentv.com/story/31154729/plaintiff-files-xarelto-lawsuit-claiming-anticoagulant-caused-mans-uncontrollable-internal-bleeding-death
-
Feb 8, 2016 | Berstein Liebhard LLP
Thousands of Xarelto lawsuits (www.rxinjuryhelp.com/xarelto/lawsuit) continue to move forward in the federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, where the most recent monthly Status Conference was convened on January 22, 2016. A Minute Entry notes that, among other things, the parties exchanged bellwether trial selections on January 11th, while random selections were made on January 15th. The Entry also indicates that the Court will hear oral arguments on a proposed order governing the parties’ interactions with plaintiffs’ prescribing and treating physicians on February 23rd, immediately following the Status Conference scheduled for that date. (In Re: Xarelto Products Liability Litigation, No. 2592)
"Our Firm is representing a number of Xarelto plaintiffs in this proceeding. We are pleased that these cases are progressing, especially in regards to bellwether trials. Such trials are intended to test the strength of plaintiffs’ allegations, and can provide insight into potential jury decisions in similar cases," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.
Xarelto Lawsuits Mount
According to court documents, more than 2,800 Xarelto lawsuits are now pending in the Eastern District of Louisiana. All of the cases put forth similar allegations regarding the anticoagulant’s potential to cause uncontrollable internal bleeding and other problems. Among other things, plaintiffs claim that Xarelto’s manufacturers failed to provide adequate warnings regarding its serious risks, and wrongly promoted the medication as a superior alternative to warfarin. They note that bleeding associated with the much older blood thinner can be reversed via the administration of vitamin K. However, there is currently no approved antidote to stop Xarelto bleeding events.
Xarelto was approved by the U.S. Food & Drug Administration (FDA) in 2011, and is currently indicated to prevent strokes in atrial fibrillation patients; to treat deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee implant surgery. Xarelto’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.
Xarelto patients who allegedly experienced uncontrollable gastrointestinal bleeding, cerebral bleeding or other episodes of internal hemorrhaging may be eligible to join the litigation involving the blood thinner. To find out more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.
http://www.digitaljournal.com/pr/2829158#ixzz3zbbvkgRq -
Xarelto Lawsuit Alleges Manufacturers Fraudulently Marketed Blood Thinning Drug
Feb 8, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against the manufacturers of anticoagulant Xarelto: Janssen Pharmaceuticals (part of the Johnson & Johnson corporation) and Bayer AG. This complaint alleges that each of these companies has fraudulently misrepresented the risks and benefits of the blood thinner through misleading marketing tactics. The complaint encompasses a total of 32 counts and was filed in theSt. Clair County Circuit Court on October 13, 2015, under case number 15-L-581.
The lawsuit additionally alleges that these manufacturers neglected to adequately warn doctors of the potentially dangerous side effects that may be caused by their blood thinner, specifically, at the time, its complete lack of an antidote. In court documents, the plaintiff notes that Xarelto was misleadingly marketed, with commercials that focused on the drug’s benefits and neglected to discuss the dangers, and the use of celebrity appearances. The man is seeking damages exceeding $50,000, as well as money to cover legal fees that his lawsuit might incur.
Xarelto lawsuits have been increasingly filed from across the nation in recent months and have surpassed 3,000 in number at this time. In federal court, 2,800 Xarelto lawsuits have been consolidated by the U.S. JPML to form MDL 2592. In addition to these cases, another group of over 550 cases has been consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas. These cases all share strikingly similar allegations against the same defendants, claiming that Xarelto use can put patients at increased risk for sudden, dangerous, and uncontrollable bleeding episodes; both internal and external. The cases which were formed into MDL 2592 are now being overseen by the Honorable Judge Eldon Fallon in Eastern Louisiana.
Cases involved in Judge Fallon’s MDL are expected to continue to increase in number as they await bellwether trials, which the Honorable Judge has scheduled for early 2017. Attorney Joseph Osborne is currently working to do his part to ensure that everyone who has been negatively affected by Xarelto will have the ability to explore their legal rights. He is offering complimentary consultations to affected parties. These people may be entitled to legal action and substantial compensation.
For additional information on Xarelto bleeding lawsuits, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.12newsnow.com/story/31171672/xarelto-lawsuit-alleges-manufacturers-fraudulently-marketed-blood-thinning-drug
-
Feb 8, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the results of several studies which have stirred up new concerns over the use of blood thinner Xarelto by linking it to dangerous, sudden bleeding episodes in patients. This supports the arguments of the many plaintiffs who have recently filed lawsuits against Xarelto, who all commonly allege that the anticoagulant can cause serious and even fatal uncontrollable bleeding side effects for those using it.
In 2011, The U.S. Food and Drug Administration (FDA) approved Xarelto to treat patients who may be at increased risk for blood clots or stroke. It was intended to be given to those recovering from hip or knee replacement surgeries, those with deep vein thrombosis or pulmonary embolism, and those who suffered from atrial fibrillation. As a new-generation blood thinner, Xarelto generated lots of excitement upon its initial launch. Not long after this buzz, however, the public began to link the drug to some potentially dangerous side effects.
Talk of these dangerous side effects spurred doctors Judy Hun and John Hwang to take matters into their own hands, and further investigate the blood thinner’s effects on their own patients. At one time in their practice, they noticed several of their patients had developed “spontaneous vitreous hemorrhage” (an episode of eye bleeding) while taking Xarelto. After studying this potential link, the doctors concluded risks of these eye bleeds may be elevated for patients who had switched from using traditional blood thinners to Xarelto.
This study was not the only one to link Xarelto use to bleeding episodes. An additional study which was done from October 1st of 2010 to March 31st of 2012 evaluated a large number of people from across the nation who had used either Xarelto, Pradaxa, or warfarin as anticoagulants. In observing a sample of 46,000 patients, including 39,607 who took warfarin, 4,907 who took Pradaxa, and 1,649 who took Xarelto, results indicated “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”
Today, lawsuits which have been filed against Xarelto manufacturers have reached over 2,800 cases in federal court, and an additional mass tort group of 550 cases has been consolidated in Philadelphia, PA. The federal cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 and are currently being overseen by the Honorable Judge Eldon Fallon in Louisiana.
Attorney Joseph Osborne is now working to help assist anyone who used Xarelto and suffered from adverse health events. He believes that these individuals may be entitled to substantial compensation and that they deserve the opportunity to fully explore their legal rights. At this time, he is offering complimentary legal consultations to affected individuals.
To obtain additional information or to ask questions, please call Attorney Osborne at (866) 425-8902.
http://www.digitaljournal.com/pr/2828894#ixzz3zgnvkn38
-
Xarelto Lawsuit Plaintiff Claims Manufacturers Use Misleading Advertisements for Anticoagulant
Feb 9, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against the makers of blood-thinning drug Xarelto, Bayer AG and Janssen Pharmaceuticals. The complaint discusses recent marketing advertisements which the plaintiff indicates are intentionally misleading. The drug, which is currently the subject of over 2,800 federal court lawsuits and over 550 lawsuits in a Philadelphia, Pennsylvania mass tort group, still uses the endorsements of famous celebrities in its ads, which focus heavily on the good and, according to the plaintiff, do not adequately discuss Xarelto’s potentially dangerous side effects.
Celebrities shown in Xarelto advertisements include many athletes: Brian Vickers (a NASCAR driver), Chris Bosh (an NBA player), Kevin Nealon (a famous SNL alumni), and Arnold Palmer (a retired golf legend). Through these TV commercials, each of the celebrities talks about their personal experiences with the Xarelto, which, greatly focus on all of the positives of the new-generation blood thinner.
In his lawsuit, the plaintiff closely examines these tactics and claims that there is a great deal of information missing on adverse health events that the drug has been linked to by several studies, and many individuals who have taken it. He claims that the manufacturers have been negligent in providing adequate information to the public about potential uncontrollable bleeding episodes, which may be caused by the blood thinner.
Several studies done on Xarelto have shown that users who switch from traditional blood thinners to the newer anticoagulant may be at increased risk for stomach and eye bleeds. Plaintiffs involved in the many lawsuits filed against Bayer and Janssen allege that the drug caused dangerous bleeding episodes, some of which proved fatal.
Xarelto lawsuits which were federally-filed have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 and are being overseen in the Eastern District of Louisiana by Judge Eldon Fallon. Their numbers have skyrocketed since the initial formation of the MDL, and many believe that as the cases await trial preparations, they will continue to increase in number. For this reason, Attorney Joseph Osborne is working to help ensure that everyone who believes they were negatively affected by the blood thinner will have the opportunity of fully investigate their legal rights. At this time, Attorney Osborne is offering complimentary Xarelto consultations for those who have been affected by the drug.
To ask questions or request additional Xarelto lawsuit information, please call Joseph Osborne, Esq. at (866) 425-8902.
http://www.digitaljournal.com/pr/2830785#ixzz3zmGM8dwX
-
Vermont Plaintiff Files Xarelto Lawsuit Alleging Drug Caused Father's Fatal Uncontrollable Bleed
Feb 9, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit filed against the manufacturers of anticoagulant Xarelto: Bayer AG and Janssen Pharmaceuticals, (a division of the Johnson & Johnson corporation). The lawsuit was filed under case number 2:14-cv-00159-CR by a daughter on behalf of her deceased father in a Vermont federal courtroom. The complaint alleges that the plaintiff’s father’s uncontrollable bleeding episode and subsequent death was caused by Xarelto.
Further lawsuit details found within court documents show that the father was prescribed blood-thinning drug Xarelto in order to treat his atrial fibrillation condition. This is a heart condition that can sometimes put patients at increased risk for blood clots or strokes. Many patients who are diagnosed with the condition choose to use blood thinners as a preventative measure for these occurrences.
Although the father had taken Xarelto only a short time, when he suddenly injured himself and suffered a brain bleed, doctors could not get the blood to clot. He was diagnosed with a parenchymal hemorrhage, which is a type of intracerebral hemorrhage, and doctors worked to keep him alive for 6 days until he ultimately passed away from the bleed.
At the time of the plaintiff’s father’s bleed, Xarelto had no available antidote. The drug was sold to consumers without an antidote for four years, in fact. When patients who had taken Xarelto were injured and bleeding, doctors had nothing to treat them with to allow their blood to clot and prevent them from bleeding out. In these situations, the treating physicians would resort to extreme, life-saving measures such as surgeries or blood transfusions.
Traditional blood thinners, such as warfarin, were released with an available antidote through vitamin K. If someone who had used these types of blood thinners began to bleed, physicians were able to treat them with vitamin K, which would counteract the anticoagulant’s effects and allow their blood to form clots.
The plaintiff’s lawsuit claims that, at the time of her father’s death, manufacturers Janssen and Bayer showed reckless negligence by initially releasing a drug for consumer sales which had no corresponding antidote, and which could pose so many significant and potentially fatal bleeding dangers. In making these claims, the young woman is not alone. At this time, more than 2,800 federally-filed Xarelto lawsuits have been filed and consolidated by the U.S. Judicial Panel on Multidistrict Litigation under MDL number 2592. In addition to these, more than 550 other Xarelto lawsuits have been consolidated to form a mass tort litigation group in Philadelphia, Pennsylvania.
Attorney Joseph Osborne is currently working to help make sure that anyone who has been negatively affected by adverse health events associated with Xarelto will have the opportunity to fully explore their legal rights. These people may be entitled to substantial compensation. Attorney Osborne is offering complimentary legal consultations to affected individuals at this time.
To request more information on Xarelto lawsuits, or ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2831015#ixzz3zmGhKHuF
-
Xarelto Lawsuit Study Published by BMJ Notes Possible Twofold Increase in GI Bleed Risk
Feb 9, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the concerning results of several studies that appear to connect the use of anticoagulant Xarelto to increased risk of dangerous bleeding episodes, such as spontaneous vitreous hemorrhages, (also known as eye bleeds), and internal gastrointestinal bleeds.
The number of lawsuits concerning Xarelto and filed against Bayer AG and Janssen Pharmaceuticals continues to increase, and, as they do, public focus has shifted to the current multidistrict litigation which is comprised of over 2,800 of these cases. Both plaintiffs and the general public are now addressing the potentially severe side effects of Xarelto. Several especially notable studies have given plaintiffs important information as they look forward to pursuing justice through trials.
On June 25, 2015, JAMA Ophthalmology published a study highlighting a connection found by researchers between consumer use of rivaroxaban (Xarelto’s generic counterpart) and a heightened risk of spontaneous vitreous hemorrhaging within the eyes. Doctors conducting the research also found that “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.”
Xarelto is currently the subject of two black box warnings from the U.S. Food and Drug Administration. This is the most strict warning a product can be given before it is fully removed from the market. These new results suggest that the dangerous side effects connected to the drug are things that the public should be especially aware of, specifically those consumers who may be switching to use Xarelto after using a traditional anticoagulant.
Another study which linked some potential risks to Xarelto was published in BMJ in April of 2015, and its results noted that Xarelto (rivaroxaban) use may as much as double a patient’s risk of suffering gastrointestinal bleeds when compared with those taking warfarin (a traditional blood thinner). Upon completing the study, the researchers stated, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”
Attorney Joseph Osborne understands the devastating and potentially fatal effects of serious bleeding episodes. He is currently working to assist anyone who has not yet filed a Xarelto lawsuit, but who has suffered from serious health issues that they connect to the drug. He feels that these individuals are entitled to the opportunity to fully explore their legal rights. They may be able to gain significant compensation. To encourage their pursuit of justice, Attorney Osborne is offering free legal consultations for those who qualify at this time.
To request more Xarelto lawsuit information or ask questions, contact attorney Joseph Osborne by calling (866) 425-8902.
http://www.12newsnow.com/story/31182897/xarelto-lawsuit-study-published-by-bmj-notes-possible-twofold-increase-in-gi-bleed-risk
-
Xarelto Lawsuit Plaintiff Draws Questions Surrounding Drug’s 24 Hour, One-Pill Dosage
Feb 10, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an especially remarkable Xarelto lawsuit which was filed in a State Court in Pennsylvania. The suit names Xarelto manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson) as the defendant, and is especially notable as it poses a different claim than many of the others. The suit claims that the drug’s recommended one pill per day dose is ineffective for a full 24-hours. Court document details support this claim, as they explain that the plaintiff suffered a stroke only four days after beginning to take Xarelto. Ironically, the man was taking Xarelto in order to prevent the very occurrence of a stroke due to his atrial fibrillation condition.
The one pill per day dosage instructions on Xarelto are unlike dosage suggestions on any other blood thinner. No other blood thinner offers one pill per day, one-size-fits-all dosing. Some argue that this is because this dosing option is insufficient. Whatever the reason, all other blood thinners require at least 2 doses of medication each day.
After suffering from his stroke, the plaintiff moved to file suit against the drug manufacturer on October 8, 2015. He not only states that the drug was not effective for a 24-hour period to prevent his stroke, but he also claims that Xarelto may have even caused the occurrence of his stroke. The anticoagulant has recently been the subject of over 2,800 federally filed lawsuits and over 550 consolidated lawsuits which form a mass tort group in Philadelphia, Pennsylvania. These lawsuits, however, commonly allege that the drug causes an increased risk for dangerous and uncontrollable bleeding episodes.
In 2011, the U.S. Food and Drug Administration (FDA) approved Xarelto for use by patients recovering from knee and hip surgeries or those suffering from deep vein thrombosis. They later expanded this approval to include those with atrial fibrillation, a common heart condition which can put patients at increased risk for stroke. When it launched onto the market as a revolutionary, new-generation blood thinner; it immediately became a popular drug. Today, many who once chose it are questioning that choice.
The 2,800 Xarelto lawsuits which were filed in federal courts across the U.S. have now been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592.
They are being overseen in Louisiana by U.S. District Judge Eldon E. Fallon, and their bellwether trials are expected to be heard in early 2017. As they await further trial preparations, many expect that additional lawsuits will be filed and will join the MDL.
At this time, Attorney Joseph Osborne is working to help ensure that anyone suffering after taking Xarelto will be given the opportunity to explore their legal rights in full. He is currently offering complimentary consultations to affected parties, who may be entitled to substantial compensation.
To request additional information, or to ask questions, please contact Joseph Osborne, Esq. by calling 866-425-8902.
http://www.digitaljournal.com/pr/2832741#ixzz3zy9cVheC
-
Xarelto Lawsuits Continue Their Steady Progression As Plaintiffs Look To February Status Conference
Feb 10, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto lawsuits consolidated in MDL No. 2592, which continue to progress in the U.S. District Court for the Eastern District of Louisiana. The latest monthly status conference for these lawsuits was held on January 22nd of 2015, where those involved shared bellwether trial selections. In addition, according to the minute entry notes of that meeting, the Court is said to hear arguments concerning a proposed order governing interactions between the plaintiffs’ physicians and the parties, which is currently scheduled to take place on February 23rd, just after the next monthly status conference, which will be held on the same day.
Xarelto lawsuits were consolidated to form multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict litigation. This consolidation helps to ‘fast track’ the litigation process by helping avoid different rulings from more than one judge, as well as duplicate discovery items. In addition, it conserves resources for those involved. This consolidation was possible due to the strikingly similar claims contained in each lawsuit, and due to the fact that all lawsuits named the same defendants, (Bayer AG and Janssen Pharmaceuticals; a subdivision of the Johnson & Johnson corporation).
Court documents show a continued rise in lawsuits filed against Xarelto, with more than 2,800 federal court cases now consolidated in the MDL, and another group of over 550 cases which have been formed into a mass tort group in Philadelphia, Pennsylvania. Plaintiffs filing these cases commonly allege that blood-thinning drug Xarelto poses an increased risk to patients taking it for uncontrollable bleeding episodes, and other serious health complications. They also claim that manufacturers Janssen and Bayer neglected to properly warn the public about the drug’s risks, and instead misleadingly marketed it.
In 2011, the U.S. Food and Drug Administration approved Xarelto to treat patients healing after hip and knee replacement surgeries, as well as patients with pulmonary embolism or deep vein thrombosis. Shortly after this initial approval, the FDA expanded its approval to include treatment for patients with atrial fibrillation, who could be at increased risk for strokes.
The FDA has given Xarelto two black box warnings, which are the most severe warnings a product can get before being pulled completely from the market. Plaintiffs who have now filed suit against the drug claim that these serious warnings are just not enough. Plaintiffs are made up of those who have used Xarelto and have suffered from serious health events which they claim were caused by the drug, and family members representing loved ones who have passed away due to bleeding complications which they allege were linked to Xarelto use.
Attorney Joseph Osborne is now attempting to help ensure that everyone who has used Xarelto and suffered from adverse health effects will be given an opportunity to fully evaluate their legal options. These consumers may be entitled to significant compensation. To encourage their pursuit of justice, Attorney Osborne is offering free Xarelto consultations at this time.
To ask questions or request more information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2832972#ixzz3zyA2niuW
-
Xarelto Lawsuit Plaintiff Draws Questions Surrounding Drugs 24 Hour, One-Pill Dosage
Feb 10, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an especially remarkable Xarelto lawsuit which was filed in a State Court in Pennsylvania. The suit names Xarelto manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson) as the defendant, and is especially notable as it poses a different claim than many of the others. The suit claims that the drug’s recommended one pill per day dose is ineffective for a full 24-hours. Court document details support this claim, as they explain that the plaintiff suffered a stroke only four days after beginning to take Xarelto. Ironically, the man was taking Xarelto in order to prevent the very occurrence of a stroke due to his atrial fibrillation condition.
The one pill per day dosage instructions on Xarelto are unlike dosage suggestions on any other blood thinner. No other blood thinner offers one pill per day, one-size-fits-all dosing. Some argue that this is because this dosing option is insufficient. Whatever the reason, all other blood thinners require at least 2 doses of medication each day.
After suffering from his stroke, the plaintiff moved to file suit against the drug manufacturer on October 8, 2015. He not only states that the drug was not effective for a 24-hour period to prevent his stroke, but he also claims that Xarelto may have even caused the occurrence of his stroke. The anticoagulant has recently been the subject of over 2,800 federally filed lawsuits and over 550 consolidated lawsuits which form a mass tort group in Philadelphia, Pennsylvania. These lawsuits, however, commonly allege that the drug causes an increased risk for dangerous and uncontrollable bleeding episodes.
In 2011, the U.S. Food and Drug Administration (FDA) approved Xarelto for use by patients recovering from knee and hip surgeries or those suffering from deep vein thrombosis. They later expanded this approval to include those with atrial fibrillation, a common heart condition which can put patients at increased risk for stroke. When it launched onto the market as a revolutionary, new-generation blood thinner; it immediately became a popular drug. Today, many who once chose it are questioning that choice.
The 2,800 Xarelto lawsuits which were filed in federal courts across the U.S. have now been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592.
They are being overseen in Louisiana by U.S. District Judge Eldon E. Fallon, and their bellwether trials are expected to be heard in early 2017. As they await further trial preparations, many expect that additional lawsuits will be filed and will join the MDL.
At this time, Attorney Joseph Osborne is working to help ensure that anyone suffering after taking Xarelto will be given the opportunity to explore their legal rights in full. He is currently offering complimentary consultations to affected parties, who may be entitled to substantial compensation.
To request additional information, or to ask questions, please contact Joseph Osborne, Esq. by calling 866-425-8902.
http://www.wrcbtv.com/story/31193387/xarelto-lawsuit-plaintiff-draws-questions-surrounding-drugs-24-hour-one-pill-dosage
-
Feb 11, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on bellwether trial dates which have been set for Xarelto-related lawsuits consolidated in multidistrict litigation no. 2592. The MDL cases are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana and underwent bellwether trial preparations in early January of 2016.
According to court documents regarding the MDL, the initial two bellwether trials are set to be heard on February 6 and March 13 of 2017. The final two of four will then take place on April 24 and May 30 of 2017. Xarelto MDL lawsuits have continued to rise in number and now involve over 2,800 cases with plaintiffs who share strikingly similar allegations that Xarelto puts those taking it at increased risk of uncontrollable bleeding episodes.
The blood thinning drug has been linked to gastrointestinal bleeding, strokes, blood clots, stomach bleeds, eye bleeds, and brain hemorrhages by those who have used it, and by recent medical research. Plaintiffs claim that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals failed to sufficiently warn consumers about these risks. They commonly agree that advertising for the drug is misleading in that it does not mention many of these concerns.
According to the overseeing judge’s requests, at this time, the court, the plaintiffs, and the defendants should have chosen 40 cases to make up a bellwether pool and have also likely chosen four of those 40 cases to continue to bellwether trials in 2017. The upcoming bellwether trials are designed to provide everyone involved with a better idea of how juries are likely to respond to certain testimony and evidence in future trials.
Attorney Joseph Osborne is currently working to help ensure that anyone who has used Xarelto and who later suffered from adverse health events will have the opportunity to explore their legal options in full. These individuals could be entitled to significant compensation. To help those deserving pursue justice, Attorney Osborne is also offering free Xarelto consultations at this time.
For more information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2834276#ixzz3zy8LlrQQ
-
Feb 11, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the steady increase of Xarelto lawsuit numbers being consolidated to form a mass tort group in Philadelphia, Pennyslvania by the Court of Common Pleas. These lawsuits were commonly filed against defendants Bayer AG and Janssen Pharmaceuticals, (whose parent company is corporate giant Johnson & Johnson).
Involved plaintiffs similarly allege that blood-thinning drug Xarelto puts patients at increased risk of suffering from sudden uncontrollable bleeding episodes as well as several other serious and potentially fatal side effects. At this time, the mass tort group reportedly involves over 550 cases.
The plaintiffs who have stepped forward to file these lawsuits are not alone in their allegations. In New Orleans, Louisiana more than 2,800 other Xarelto lawsuits have been consolidated to form MDL 2592. These cases were transferred to a single court after being filed in federal courts across the nation, and were filed by plaintiffs who are making very similar allegations against Janssen and Bayer. Some plaintiffs involved in the lawsuits have filed on behalf of loved ones who have passed away after suffering from uncontrollable bleeding episodes while taking Xarelto.
Not only do plaintiffs in each group of cases allege that the blood thinner has uncontrollable bleeding risks, they also allege that manufacturers failed to adequately inform the consumers about these risks, and used misleading advertising tactics to focus solely on the benefits of the new-generation anticoagulant. It was additionally noted that Xarelto marketing relied on celebrity endorsements from well-known athletes.
Cases in both the Pennsylvania and Louisiana groupings continue to grow in number as they are prepared for trial. Plaintiffs find hope from the results of recent lawsuits filed against similar blood thinner Pradaxa, which ended in a settlement.
Attorney Joseph Osborne is now working to help ensure that all people who may have suffered from uncontrollable bleeding while taking Xarelto will have the opportunity to investigate their legal options. These individuals and their families may be entitled to legal action and substantial compensation. To encourage their pursuit of justice as these other consolidated cases await trial, Attorney Osborne is offering free legal consultations for affected patients.
To ask questions or request further information on Xarelto lawsuits, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2834618#ixzz3zy95AtOo
-
Xarelto Lawsuits Now Exceed 3,000 in Number
Feb 11, 2016 | Legal-Bay
By Patty Kirby
Legal-Bay LLC, The Lawsuit Settlement Funding Company, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division are now more than 3,000 in number. Just last month, the number of cases were at approximately 2,400. Now, according to the Blood Thinner Help website, 2,800 cases have been consolidated in the Eastern District of Louisiana, with an additional 550 lawsuits consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania (MDL 2592).
Four bellwether trials are set to begin in February of 2017. The first two trials are set to take place in the Eastern District of Louisiana on February 6th, 2017 and March 13th, 2017. The third and fourth trials will take place in Mississippi and Texas on April 24th, 2017 and May 30th, 2017. The lawsuits include claims of serious health problems, long hospital stays, and even death as a result of uncontrollable bleeding events. According to experts, there is no known antidote at this time. For more information or assistance with finding a qualified Xarelto law firm or Xarelto lawyer, contact Legal-Bay directly at: http://lawsuitssettlementfunding.com/contact-us.php
Chris Janish, CEO of Legal-Bay, commented on the recent announcement in the Xarelto multidistrict litigation, "We expected the Xarelto litigation to pick up steam, and it seems that it's happening, as more and more lawsuits continue to be filed. We are following this litigation closely, and we want to remind patients who have been injured by the blood thinner that we are committed to helping them."
In order to receive lawsuit funding, you must have retained a Xarelto lawyer first. If you need lawsuit money or pre-settlement funding for your Xarelto claim, Legal-Bay is here to help. Legal-Bay is offering pre-settlement and settlement funding for Xarelto cases as well as other blood thinners – such as Pradaxa – and they are also providing free legal consultations for possible plaintiffs who have not yet retained a Xarelto lawyer. To learn more about Xarelto, Pradaxa, and other blood thinner cases, including services in helping you find a Xarelto lawyer or Xarelto law firm, visit: http://lawsuitssettlementfunding.com/pradaxa-settlement-funding.php
To speak with a live agent to discuss receiving pre-settlement lawsuit money or a free legal consultation on your potential Xarelto or Pradaxa blood thinner lawsuit, call Legal-Bay's toll-free hotline at: 877.571.0405.
You may also apply online at: http://lawsuitssettlementfunding.com and an agent will respond to your request shortly.
http://www.newschannel10.com/story/31197939/xarelto-lawsuits-now-exceed-3000-in-number
-
New Jersey Woman Blames Xarelto for Life-Threatening Bleeding
Feb 9, 2016 | Legal Examiner
By Kendra Goldhirsch
On December 28, 2015, another Xarelto lawsuit joined the centralized litigation in the Eastern District of Louisiana. The plaintiff, a resident of New Jersey, brought claims against manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson, and Bayer Pharma AG.
There are currently over 2,400 Xarelto lawsuits pending in Louisiana, in which plaintiffs claiming that the manufacturers failed to warn about serious risks associated with the blood-thinning drug, including serious gastrointestinal bleeding that can lead to death.
Plaintiff Claims Xarelto Caused Life-Threatening Bleeding
According to her complaint, the plaintiff took Xarelto as prescribed from around November 2013 to April 2014. On March 11, 2014, and again on April 2, 2014, she suffered severe gastrointestinal bleeding, which she claims was caused by Xarelto.
As a result of her injuries, the plaintiff alleges that she had to be hospitalized for the bleeding, and suffered life-threatening effects. She seeks compensation for medical expenses and other non-economic damages.
ROCKET AF Study Poorly Managed to Show Xarelto’s Superiority
The FDA first approved Xarelto in July 2011 to help reduce the risk of blood clots in patients undergoing knee and hip replacement surgery. It later approved the drug for patients with non-valvular atrial fibrillation, to reduce the risk of stroke, and in 2012, to help treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).
The plaintiff points out that even in the early clinical trial used to gain FDA approval for patients with non-valvular atrial fibrillation (the ROCKET AF trial), Xarelto was associated with an increased risk of gastrointestinal bleeding, which occurred more often in patients taking Xarelto than in those taking warfarin, the leading anti-coagulant for decades.
She also alleges that the warfarin group in that study was poorly managed: “The warfarin group in the ROCKET AF study was the worst managed warfarin study group in any previously reported clinical trial involving warfarin.” She adds that the FDA noted the data comparing Xarelto to warfarin “was not adequate to determine whether Xarelto is as effective for its proposed indication in comparison to warfarin when the latter is used skillfully.”
Consumer watchdog group Public Citizen strongly opposed FDA approval of Xarelto, nothing that the ROCKET AF trial “had a suboptimal control arm…”
Plaintiff Questions Once-a-Day Dosing Rationale
When the manufacturers released Xarelto on the market, they advertised it as a superior option to warfarin because it was more convenient to use. Whereas those taking warfarin need to undergo regular blood monitoring, those taking Xarelto were given a once-a-day dose.
FDA clinical reviewers also questioned the once a day dosing and stated that data from early trials suggested that twice daily dosing might have been associated with greater efficacy and possibly a better safety profile. The plaintiff quotes Dr. Steven E. Nissen, who on an FDA advisory meeting transcript, stated “my concern was that the dose was selected more for a marketing advantage rather than for the scientific data that was available, and was a mistake…”
Finally, the plaintiff accuses Xarelto manufacturers of overly aggressive marketing of the drug, during which the manufacturers overstated the efficacy of the drug while downplaying the potential side effects. Specifically, she says they failed to tell patients and doctors that there was “no drug, agent, or means to reverse the anticoagulation effects of Xarelto,” effectively making the drug’s effects non-reversible if uncontrolled bleeding occurs in a patient. That makes any bleeding events associated with the drug not only dangerous but potentially life-threatening.
The plaintiff brings counts of strict liability, manufacturing defect, design defect, failure to warn, negligence, breach of warranties, negligent misrepresentation, and fraud.
http://newyork.legalexaminer.com/defective-dangerous-products/new-jersey-woman-blames-xarelto-for-life-threatening-bleeding/
-
Xarelto Uncontrollable Brain Bleed Lawsuits Increasing
Feb 9, 2016 | Dallas Fort Worth Injury Lawyer Blog
By Dr. Shezad Malik
Oren Fells from Georgia recently filed a Xarelto uncontrollable intracranial or brain bleeding lawsuit in the U.S. District Court for the Eastern District of Louisiana. The lawsuit was filed against Bayer Healthcare, Johnson & Johnson, and its Janssen subsidiary, the manufacturers of Xarelto.
Catastrophic Xarelto Brain Bleeding Allegations
Fells began taking the newer anticoagulant or blood thinner Xarelto in 2013, for the treatment of atrial fibrillation, a common heart rthym problem. Fells suffered a brain bleed in January, 2014, causing him to develop life long permanent injuries.
Many lawsuits have been filed against Xarelto’s manufacturers, Bayer and Johnson & Johnson and the plaintiffs claim that the companies failed to warn patients and doctors about the risks associated with Xarelto and the lack of an antidote to help stop the bleeding.
What is Xarelto?
Xarelto (rivaroxoaban) was FDA approved in 2011 as an alternative for Coumadin (warfarin), which has been the gold standard anticoagulant treatment for the past 60 years. Xarelto is one of several new-generation blood thinners, which have been promoted as easier to use than warfarin. Unfortunately, several thousand Xarelto bleeding problems have been reported since the medication was used.
Xarelto Federal MDL Litigation
According to the latest federal court census, there are almost 2,500 lawsuits filed, alleging that Xarelto caused patients to develop serious bleeding injuries. The Xarelto litigation is consolidated and centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of Multidistrict litigation (MDL) since December 2014.
Lawsuits against Bayer and Johnson & Johnson are consolidated in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort litigation court in Philadelphia.
As is common in pharmaceutical multi-district litigation, a small group of Xarelto injury cases are scheduled to go through case-specific discovery and be set for early test trials, these are known as “bellwether trials.”
4 Xarelto Bellwether Trials Set
Judge Fallon set a series of four bellwether trials to go before juries in the Spring of 2017. The number of Xarelto lawsuits continue to increase and be filed by individuals across the United States, alleging severe and deadly bleeding complications.
Bellwether Trials in Louisiana, Mississippi and Texas
The first two trials will be held in the Eastern District of Louisiana, on February 6 and March 13, 2017. The third trial will be held in Mississippi on April 24, 2017 and the fourth trial will be held in Texas on May 30, 2017.
According to Judge Fallon’s order, the cases that will go before juries on these dates will be pulled from a pool of 40 lawsuits to be selected in January 2016. These cases will be trial ready, with case-specific discovery, including depositions of plaintiffs, prescribing doctors, treating physicians and sales representatives of the drug makers.
Pradaxa MDL Settlement
Pradaxa, the first new-generation anticoagulant to hit the market was also exposed to several thousand bleeding complication lawsuits. More than 4,000 Pradaxa injury lawsuits were filed, and Boehringer Ingleheim, the manufacturer agreed to settle the claims without any trials and paid $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
http://www.dallasfortworthinjurylawyer.com/2016/02/xarelto-uncontrollable-brain-bleed-lawsuits-increasing.html
-
Xarelto Lawsuit Says Blood Thinner Caused Intracranial Bleed
Feb 9, 2016 | Top Class Actions
By Joanna Szabo
A Georgia resident recently filed a lawsuit against Janssen, a subsidiary of Johnson & Johnson, over Xarelto problems including internal bleeding in the brain.
Plaintiff Orenn F. began taking Xarelto in August 2013, as prescribed by his physician as a blood thinner for atrial fibrillation.
The Xarelto lawsuit alleges that approximately six months after using the blood thinner drug, Orenn developed a life-threatening intracranial bleed (internal bleeding in the brain) that required emergency medical intervention in January 2014.
According to the Xarelto lawsuit, Janssen failed to adequately warn consumers of the safety risks associated with its blood thinning medication. Instead, Janssen represented its drug as safe and effective to consumers, the FDA, and the medical community as a whole, actively concealing knowledge of Xarelto problems.
Orenn claims that had he been properly informed of this Xarelto side effect and other potential dangers, he would not have taken Xarelto and would have avoided its dangerous consequences. He has filed this Xarelto bleeding lawsuit on multiple counts, including failure to warn, defective design, negligence, and fraud and deceit, among several others.Xarelto Problems
Xarelto (rivaroxaban) is a popular anticoagulant medication often used to treat atrial fibrillation, as was the case for this Orenn F. Janssen, the developer, manufacturer, and marketer of Xarelto, claims that the new generation blood thinner has been prescribed to over seven million people across the world, helping prevent dangerous blood clots.
However, according to many of these Xarelto lawsuits, Janssen deliberately underplayed the drug’s safety and efficacy. Rather than being superior to warfarin (an anticoagulant staple drug), many plaintiffs claim the blood thinner is allegedly no safer to use, and like warfarin, should require routine blood monitoring to be safe.
Not all side effects of Xarelto are severe or dangerous, and not all users of Xarelto experience side effects. Those who do, however, can be subject to extremely severe and dangerous bleeding issues that cannot be controlled or reversed, given that there is no antidote to counteract Xarelto’s effects.
This Xarelto bleeding lawsuit and others like it allege that a series of clinical trials well known in the medical community has revealed a link between Xarelto and major bleeding events, such as gastrointestinal bleeding. The studies indicated that Xarelto had an even higher rate of major bleeding complications than other, similar drugs, including generic warfarin.
“Major bleeding” indicates that the bleeding involved a critical organ, led to reoperation, or led to fatalities.
Xarelto bleeding lawsuits claim that Janssen was not only aware of these studies and the bleeding risks of the drug, but failed to report these major bleeding complications as significant adverse effects. On top of this, the lawsuits allege that Janssen failed to adequately warn consumers and the medical community about dangerous Xarelto problems.
Despite the manufacturer’s alleged knowledge of these risks, the company continued to market Xarelto in a manner the lawsuit describes as negligent and misleading, diminishing the concern for the serious risks of the drug.Xarelto Bleeding Lawsuits
Xarelto is currently facing hundreds of Xarelto bleeding lawsuits filed for patients who, after taking Xarelto, have experienced gastrointestinal bleeding, hemorrhaging, or another reported Xarelto side effect.
Plaintiffs claim that the drug manufacturers did not clearly portray the drug’s potentially damaging side effects on their packaging, in their advertising, or to the medical community as a whole.
If you or someone you know has experienced a life-threatening Xarelto side effect such as intracranial or gastrointestinal bleeding, you may be entitled to compensation for your pain and suffering.
The Xarelto Bleeding Lawsuit is Case No. 2:16-cv-00241, in the U.S. District Court for the Eastern District of Louisiana.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply
http://topclassactions.com/lawsuit-settlements/lawsuit-news/317714-georgia-man-files-xarelto-lawsuit-intracranial-bleed/
-
Can Xarelto Trial Data Be Trusted? It Depends Who You Ask
Feb 10, 2016 | LawyersAndSettlements.com
By Heidi Turner
As more Xarelto lawsuits are added to the multidistrict litigation, concerns have been raised that a medical device used in Xarelto’s clinical trial was faulty, which may have affected test results. Now critics are asking for an investigation, while Janssen Pharmaceuticals and the study’s authors maintain the study’s conclusions are accurate.
The study in question is the ROCKET-AF trial (Rivaroxaban Once Daily Oral Direct Factor XA Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), which was published in 2011 in the New England Journal of Medicine. That study found that both rivaroxaban (the generic version of Xarelto) and warfarin - the older-generation anticoagulant - each reduced the risk of ischemic stroke or systemic embolism. The study also found no significant difference between rivaroxaban and warfarin in the risk of a major bleeding event, but found rivaroxaban was associated with a lower risk of bleeding in the brain and fatal bleeding.
According to editors at The BMJ (2/3/16), Janssen and Bayer Pharmaceuticals relied only on ROCKET-AF when it applied for approval from the FDA and European regulators. The study used a device called an INRatio Monitor System, which measures how long it takes for blood to clot and which was recalled in December 2014 due to “clinically significantly lower” test results than patients might see in laboratory testing.
“A falsely low reading could mean that patients had their warfarin dose unnecessarily increased, leading to a great risk of bleeding,” Deborah Cohen writes in The BMJ. “In terms of the trial results, it could make rivaroxaban seem safer than it was in terms of the risk of bleeding and throws doubt on outcomes used to support the use of the world’s best selling new oral anticoagulant.”Some critics have now called for an independent investigation of the ROCKET-AF trial, to determine whether the results were skewed by the recalled device. The FDA reportedly told The BMJ that it would review relevant data. Representatives for the device maker, meanwhile, said their own analysis confirmed the results of the study.
In a letter to The New England Journal of Medicine (2/3/16), the study’s authors reviewed data and found that the possible malfunction of the device “did not have any significant clinical effect on the primary efficacy and safety outcomes in the trial.” The European Medicines Agency has also said in a news release posted on its website that the recalled device did not affect the results of the ROCKET-AF trial.
As of January 15, 2016, there were 2,826 lawsuits consolidated for pretrial proceedings in MDL-2592, In Re: Xarelto (Rivaroxaban) Products Liability Litigation before US District Judge Eldon E. Fallon.https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-35-21262.html
-
Georgia Man Suffers Brain Hemorrhage After Taking Xarelto
Feb 11, 2016 | Legal Examiner
By Roopal Luhana
On January 9, 2016, another Xarelto lawsuit joined the consolidated litigation in the Eastern District of Louisiana. The MDL was sent there in December 2014.
This time, the plaintiff, a resident of Georgia, brings claims against Xarelto manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson, and Bayer AG, seeking in excess of $75,000 in damages after taking Xarelto and allegedly suffering serious injuries.
Plaintiff Suffers from Brain Hemorrhage After Taking Xarelto
According to his complaint, the plaintiff was prescribed Xarelto for the treatment of his non-valvular atrial fibrillation, which is a heart rhythm disorder that increases the risk of stroke. The FDA approved Xarelto for the treatment of this condition in 2011.
The plaintiff began taking Xarelto, per his doctor’s instructions, around August 2013. A few months later, on January 11, 2014, he suffered a life-threatening intracranial bleed or brain hemorrhage. Because Xarelto has no readily available antidote, the bleeding was irreversible, and the plaintiff had to just “wait it out” until the drug cleared from his system.
The plaintiff alleges that as a result of this injury, he continues to suffer from lasting medical side effects, and has suffered a diminished enjoyment of life.
FDA Reviewers Questioned Once-a-Day Dose
Xarelto is a type of blood thinner known as a “factor Xa inhibitor,” and is available in oral tablet doses of 20 mg, 15 mg, and 10 mg. One of the things the defendants advertised was how convenient the medication was, especially in comparison to warfarin, the leading anticoagulant for decades. Unlike patients taking warfarin, those taking Xarelto don’t have to go through blood monitoring, and took a convenient once-a-day dose instead of the twice-a-day regular dosing with Warfarin.
Yet in its Quarterwatch publication for the first quarter of 2012, the Institute for Safe Medication Practices (ISMP) noted that, even during the approval process, FDA reviewers questioned the once-a-day dosing scheme, noting that blood level studies had shown “peaks and troughs” that could be eliminated by twice-a-day dosing.
The peaks and troughs seen with one-a-day dosing can be shown by blood tests. Having them indicates that the drug is not acting consistently in the patient, causing more “thinning” than expected at times, and less at other times, which can increase the risk of uncontrollable bleeding in patients taking Xarelto.
The defendants also neglected to warn on their product materials that Xarelto had no readily available antidote. Patients taking warfarin can be treated with vitamin K injections should they suffer excessive bleeding. Patients taking Xarelto, like the plaintiff, have no such option, which makes bleeding potentially much more dangerous.
FDA Sends Warning Letter to Xarelto Manufacturers
The plaintiff in this case also notes that Xarelto manufacturers received a warning letter from the FDA in 2013, because of their misleading advertising. The FDA targeted promotional material for Xarelto and atrial fibrillation, noting that “the print ad is false or misleading because it minimizes the risks associated with Xarelto and makes a misleading claim” regarding dose adjustments.
In the year leading up to June 30, 2012, the FDA received over 1,000 adverse event reports associated with Xarelto. A total of 65 of those involved patients who had died because of injuries or complications. At the end of the 2012 fiscal year, over 2,000 such reports were filed with the FDA. Yet the manufacturers, according to the plaintiff, failed to take appropriate action to protect the public.
http://newyork.legalexaminer.com/uncategorized/georgia-man-suffers-brain-hemorrhage-after-taking-xarelto/
-
Blood Thinner Lawsuit: Xarelto Causes Serious Gastrointestinal Bleeding
Feb 12, 2016 | Top Class Actions
By Ashley Vanover
Although Xarelto was approved for use in 2011 and is one of the newest blood thinners on the market, it is also the subject of lawsuits alleging that the blood thinner puts patients at risk for dangerous side effects, including life-threatening internal bleeding.
In fact, one recently filed blood thinner lawsuit joined the multidistrict litigation (MDL) against the makers of Xarelto, Bayer Healthcare and Janssen Pharmaceuticals, wherein 24 plaintiffs collectively claim that the drug caused serious bleeding events and even death.
In this Xarelto blood thinner lawsuit, North Carolina plaintiff Tandy B. alleges the companies downplayed the risk of serious gastrointestinal bleeding caused by the blood thinner, accusing the drug makers of deliberately concealing the potentially fatal side effect.
According to her Xarelto blood thinner lawsuit, Tandy used Xarelto as prescribed for approximately one month in 2014 when she then experienced serious gastrointestinal bleeding.
Tandy claims the drug should not be sold and that Bayer and Janssen negligently promoted Xarelto as safe when they allegedly knew the blood thinner could cause serious gastrointestinal bleeding.
About Xarelto
Xarelto (rivaroxaban) was first approved by the FDA in July of 2011 as a prescription medicine with three primary uses: to reduce the risk of blood clots and stroke in patients with atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism, and to reduce the risk of blood clots in patients undergoing knee or hip replacement surgery.
Xarelto belongs to a class of anticoagulants called direct factor Xa inhibitors. Sometimes referred to as blood thinners, anticoagulants interfere with the normal clotting of the blood.
Clotting is essential if a person is to stop bleeding from an open wound, but some people experience clotting when they are not injured. Atrial fibrillation is a heart condition characterized by an irregular heartbeat that can cause blood to pool in the heart and may lead to clots.
If these travel to the brain, they may cause a stroke. Blood clots that develop in the legs (deep vein thrombosis) and pulmonary embolism (blood clots in the lungs) can cause serious complications and/or death if left untreated.
Signs of Gastrointestinal Bleeding
When taking an anticoagulant drug like Xarelto, gastrointestinal bleeds can occur both in the upper and lower GI tract, posing a serious risk to the patient. If left untreated, the gastrointestinal bleed may continue unabated, ultimately reaching a critical point when blood loss becomes severe.
Regarded as a relatively common complication of Xarelto, gastrointestinal bleeding can result in hospitalization and in some cases, death.
Signs of gastrointestinal bleeding associated with Xarelto can take a number of different forms, including:
abdominal pain
a hard abdomen
vomiting blood
bloody stool
black, tar-like stool
very pale complexion
extreme tiredness
fainting
Xarelto users experiencing the above signs of gastrointestinal bleeding should seek medical treatment immediately.
Xarelto Blood Thinner Lawsuits
The FDA reports that more than 1,800 adverse events have been linked to Xarelto. The most common events were pulmonary embolism (386 reports), deep vein thrombosis (279 reports), serious gastrointestinal bleeding (107 reports) and hemorrhage (107 reports). Hospitalization was reported in 891 of these events and 183 of the patients lost their lives.
If you or a loved one has experienced serious gastrointestinal bleeding or other Xarelto bleeding side effects, it is critical to understand your legal rights in order to recover for any and all damages suffered. An experienced Xarelto attorney can carefully evaluate the facts of your particular situation and effectively pursue appropriate legal action to compensate you for your losses.
The Xarelto Blood Thinner Lawsuit is part of the Xarelto MDL, In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/312989-blood-thinner-lawsuit-claims-xarelto-causes-serious-gastrointestinal-bleeding/
-
Feb 12, 2016 | Rasanky Law Firm
Have you suffered from internal hemorrhaging or uncontrolled bleeding as a result of using the drug Xarelto®?
Individuals who are at an increased risk of blood clot formation are advised to take blood thinners by their doctors. Xarelto®, the number one blood thinner in the U.S. as of 2014, is used widely to help dissolve blood clots which could turn fatal if they traveled from their point of formation (usually deep within a vein located in the person’s leg) to the lungs or the brain.
Unfortunately, the use of Xarelto can also lead to serious internal bleeding issues which can be difficult to resolve, and which were simply not adequately marketed or labeled.
Controversial drug
Despite Xarelto’s usefulness in thinning blood and breaking up clots, the drug has come under scrutiny due to its inability to stop bleeding once it starts. This can lead to massive blood loss in just a few hours, necessitating hospitalization and blood transfusions. According to records, 65 people have died due to uncontrolled bleeding as a result of taking Xarelto. This blood thinner closely imitates Pradaxa, which has also been linked to tens of thousands individuals experiencing adverse effects, leading to dozens of lawsuits in Dallas and the whole of Texas.
Xarelto Lawsuit Lawyer in Dallas
Xarelto has serious and life-threatening side effects, with some of these being:
Major bleeding
Pulmonary embolisms
Stroke
Urinary tract bleeding
Gastrointestinal bleeding
Brain hemorrhaging
Spinal hematomas
Adrenal bleeding
Thrombosis
Unusual bruising
Inability to move extremities
If you were taking Xarelto and experienced one or more of these side effects, our Xarelto lawyers may be able to help you recover the compensation you deserve through a drug injury claim or lawsuit. If a loved one has died as a result of this medication, your family may also be able to hold the drug company liable for your loss.
Xarelto’s flaw lies in the fact that once bleeding occurs, it cannot be stopped until the drug is flushed from the victim’s system. Unlike other blood thinning drugs, Xarelto has no antidote or flushing options. Xarelto is made by pharmaceutical giant Bayer, and it is marketed in the United States by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals. Xarelto® is a brand name for rivaroxaban, a prescription drug used to prevent and treat strokes.
Affected by Xarelto? Contact us TODAY!
Dozens of lawsuits filed by people who were adversely affected by Xarelto have been recently combined into a federal MDL (multi-district litigation). If you have experienced serious bleeding issues due to taking this blood thinner, you deserve to be compensated by the company who profited. The time to act is NOW, so please contact our Dallas Xarelto lawyers today via 1-877-405-4313 or the email form found on this page. We look forward to hearing from you.
http://www.jrlawfirm.com/practice-areas/product-liability/xarelto/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested